

## *Office based non-oncology urology trials*

Richard W. Casey, MD,<sup>1</sup> Jack Barkin, MD<sup>2</sup>

<sup>1</sup>The Male Health Centre, Oakville, Ontario, Canada

<sup>2</sup>Humber River Regional Hospital, University of Toronto, Toronto, Ontario, Canada

---

### ***BENIGN PROSTATIC HYPERPLASIA***

A PHASE III STUDY OF CETRORELIX PAMOATE INTERMITTENT IM DOSAGE REGIMENS IN PATIENTS WITH SYMPTOMATIC BPH: A 1-YEAR PLACEBO-CONTROLLED EFFICACY STUDY AND LONG-TERM SAFETY ASSESSMENT

**Trial ID:** D-20762-Z033  
**Coordination:** CMX Research  
**Trial design:** To develop a safe and tolerable intermittent dosage regimen of cetorelix pamoate, that provides prolonged improvement in BPH-related signs and symptoms.  
**Patient population:** Benign prostatic hyperplasia, voiding symptoms: IPSS  $\geq$  13.  
**Sample size & endpoint:** n = 594, primary endpoint: absolute change in IPSS between baseline (week -1) and week 52. Primary safety endpoint: incidence of treatment-emergent AEs.

A PHASE II STUDY ASSESSING THE SAFETY AND EFFICACY OF A SINGLE TREATMENT OF 100 U, 200 U, or 300 U BOTOX® COMPARED WITH PLACEBO INJECTED INTO THE PROSTATE TO TREAT LOWER URINARY TRACT SYMPTOMS (LUTS) IN PATIENTS DUE TO BENIGN PROSTATIC HYPERPLASIA

**Trial ID:** 191622-517-05  
**Coordination:** CMX Research  
**Trial design:** A phase II study assessing the safety and efficacy of a single treatment of BOTOX® compared with placebo injected into the prostate.  
**Patient population:** Lower urinary tract symptoms due to benign prostatic hyperplasia.  
**Sample size:** n = 300

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-DESIGN, MULTICENTER STUDY TO EVALUATE THE URODYNAMIC EFFECT OF TADALAFIL ONCE A DAY FOR 12 WEEKS IN MEN WITH SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA

**Trial ID:** H6D-MC-LVHK(a)  
**Coordination:** CMX Research  
**Trial design:** Evaluate the effect of tadalafil 20 mg once a day compared with placebo.  
**Patient population:** Have had BPH-LUTS (as diagnosed by a qualified physician) > 6 months at visit 1. Lower urinary tract symptoms include those associated with voiding and/or storage.  
**Sample size & endpoint:** Primary endpoint: detrusor pressure at maximum flow rate (PdetQmax), which is measured during baseline and end-of-study urodynamics assessments.

## ***OVERACTIVE BLADDER***

A PHASE IIIb STUDY COMPARING THE EFFICACY OF FESOTERODINE TO PLACEBO AND TOLTERODINE ER IN SUBJECTS WITH OVERACTIVE BLADDER AFTER 12 WEEKS OF TREATMENT

**Trial ID:** A0221008  
**Coordination:** CMX Research  
**Trial design:** A 12-week, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder.  
**Patient population:** Overactive bladder with symptoms of frequency, urgency, and urgency incontinence.  
**Sample size & endpoint:** n = 1675, primary endpoint: change in mean number of urgency urinary incontinence (UUI) episodes per 24 hours at week 12 relative to the baseline.

A PHASE II STUDY TO ASSESS THE EFFICACY AND SAFETY OF MODIFIED RELEASE UK-369,003 IN THE TREATMENT OF MEN WITH STORAGE LOWER URINARY TRACT SYMPTOMS (LUTS) WITH AND WITHOUT ERECTILE DYSFUNCTION (ED).

**Trial ID:** A3711047  
**Coordination:** CMX Research  
**Trial design:** A multi-national, multi-center, double-blind, randomized, placebo-controlled, parallel group phase II study with five treatment arms.  
**Patient population:** Male aged 18 and above, with documented clinical diagnosis of OAB, with mean urinary frequency  $\geq 8$  times/24 hours, and mean number of urgency episodes with or without urgency incontinence  $\geq 1$  episode/24 hours.  
**Sample size & endpoint:** n = 300, efficacy endpoints based on: LUTS diary scores, International Prostate Symptom Score, Overactive Bladder questionnaire, Patient Perception of Bladder Condition, International Consultation on Incontinence Questionnaire, Erectile Function domain of International Index of Erectile Function, Quality of Erection questionnaire, Patient Reported Treatment Impact questionnaire, Population Pharmacokinetics.

***INTERSTITIAL CYSTITIS***

A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP EVALUATION OF THE EFFICACY AND SAFETY OF URACYST® (INTRAVESICAL SODIUM CHONDROITIN SULFATE) VERSUS VEHICLE PLACEBO IN PATIENTS WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME (IC/PBS)

**Trial ID:** UR07001  
**Coordination:** CMX Research  
**Trial design:** Prospective, randomized, double-blind, vehicle placebo-controlled, 12-week study, including a 6-week treatment period, followed by a 6-week follow-up period.  
**Patient population:** Male and females at least 18 years of age and have a clinical diagnosis of IC/PBS and who meet eligibility criteria.  
**Sample size:** n = 50

A PLACEBO CONTROLLED RANDOMIZED, 12-WEEK, DOSE-RANGING, DOUBLE-BLIND STUDY VERSUS PLACEBO USING TOLTERODINE AS A STUDY CALIBRATOR, TO EVALUATE EFFICACY AND SAFETY OF SSR240600C IN WOMEN WITH OVERACTIVE BLADDER INCLUDING URGE URINARY INCONTINENCE

**Trial ID:** DRI6271  
**Coordination:** CMX Research  
**Trial design:** A multi-center randomized, double-blind, 5-arm, parallel group study comparing three doses of SSR240600 (25, 50, and 100 mg) to placebo using tolterodine as a calibrator. The study consists of 3 phases: a) screening period of 1 week, b) double-blind treatment period of 12 weeks, and c) follow-up period of 2 weeks.  
**Patient population:** Females  $\geq 18$  and  $\leq 70$  years of age with diagnosis of overactive bladder with symptoms of urgency with urge incontinence and frequency ( $\geq 1$  urgency episode per day,  $\geq 8$  micturitions per day,  $\geq 5$  urge urinary incontinence (UUI) episodes/week), which may be associated with nocturia, but without bladder pain.  
**Sample size:** n = 800

***PREMATURE EJACULATION***

A PHASE IIb, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, WITH OPEN-LABEL FOLLOW ON, TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF PSD502 IN SUBJECTS WITH PREMATURE EJACULATION (PE)

**Trial ID:** PSD502-PE-002  
**Coordination:** CMX Research  
**Trial Design:** Phase IIb, multi-center, randomized, double-blind, placebo-controlled study. Subjects will be randomized to PSD502 or placebo in a 2:1 ratio.  
**Patient Population:** Male subjects with PE according to Diagnostic and Statistical Manual of Mental Disorders (DSM IV) criteria, aged 18 and over.  
**Sample Size:** n = 240-300